Systemic Sclerosis

Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia
Ana Luisa Oliveira, Carina Ruano, Nuno Riso, José Cepeda Ribeiro, Maria Francisca Moraes-Fontes

Annals of the Rheumatic Diseases Dec 2018, annrheumdis-2018-214747; DOI: 10.1136/annrheumdis-2018-214747
Association of circulating CXCL10 and CXCL11 with systemic sclerosis
Clara Crescioli, Clarissa Corinaldesi, Valeria Riccieri, Valeria Raparelli, Massimiliano Vasile, Francesco Del Galdo, Guido Valesini, Andrea Lenzi, Stefania Basili, Cristina Antinozzi

Annals of the Rheumatic Diseases Dec 2018, 77 (12) 1845-1846; DOI: 10.1136/annrheumdis-2018-213257
Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis
Stefano Soldano, Amelia Chiara Trombetta, Paola Contini, Veronica Tomatis, Barbara Ruaro, Renata Brizzolara, Paola Montagna, Alberto Sulli, Sabrina Paolino, Carmen Pizzorni, Vanessa Smith, Maurizio Cutolo

Annals of the Rheumatic Diseases Dec 2018, 77 (12) 1842-1845; DOI: 10.1136/annrheumdis-2018-213648
Response to: ‘Will SPAR be useful in the usual patients with scleroderma?’ by Chattopadhyay et al
Wanlong Wu, Suzana Jordan, Oliver Distler

Annals of the Rheumatic Diseases Nov 2018, annrheumdis-2018-214270; DOI: 10.1136/annrheumdis-2018-214270
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
Elizabeth R Volkmann, Donald P Tashkin, Myung Sim, Ning Li, Ellen Goldmuntz, Lynette Keyes-Elstein, Ashley Pinckney, Daniel E Furst, Philip J Clements, Dinesh Khanna, Virginia Steen, Dean E Schraufnagel, Shiva Arami, Vivien Hsu, Michael D Roth, Robert M Elashoff, Keith M Sullivan

Annals of the Rheumatic Diseases Nov 2018, annrheumdis-2018-213708; DOI: 10.1136/annrheumdis-2018-213708
Response to: ‘Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series’ by Narváez
Dinesh Khanna, Angelika Jahreis, Celia J F Lin

Annals of the Rheumatic Diseases Oct 2018, annrheumdis-2018-214477; DOI: 10.1136/annrheumdis-2018-214477
Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
Javier Narváez, Judit LLuch, Juan José Alegre Sancho, Maria Molina-Molina, Joan Miquel Nolla, Ivan Castellví

Annals of the Rheumatic Diseases Oct 2018, annrheumdis-2018-214449; DOI: 10.1136/annrheumdis-2018-214449
18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis
Silvia Bellando-Randone, Luca Tartarelli, Edorardo Cavigli, Lorenzo Tofani, Cosimo Bruni, Gemma Lepri, Jelena Blagojevic, Alberto Moggi-Pignone, Carina Mihai, Jerome Avouac, Alessandro Passeri, Maria Teresa De Cristofaro, Oliver Distler, Yannick Allanore, Serena Guiducci, Marco Matucci-Cerinic

Annals of the Rheumatic Diseases Oct 2018, annrheumdis-2018-213376; DOI: 10.1136/annrheumdis-2018-213376
Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis
Mirko Manetti, Sara Pratesi, Eloisa Romano, Irene Rosa, Cosimo Bruni, Silvia Bellando-Randone, Serena Guiducci, Enrico Maggi, Lidia Ibba-Manneschi, Marco Matucci-Cerinic

Annals of the Rheumatic Diseases Oct 2018, annrheumdis-2018-214240; DOI: 10.1136/annrheumdis-2018-214240
Patient organisation-led initiatives can play an important role in raising awareness about Raynaud’s phenomenon and encourage earlier healthcare utilisation for high-risk groups
Michael Hughes, Amy Baker, Sue Farrington, John D Pauling

Annals of the Rheumatic Diseases Oct 2018, annrheumdis-2018-214161; DOI: 10.1136/annrheumdis-2018-214161

Main menu

Systemic Sclerosis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Systemic Sclerosis

Pages